Fujifilm Diosynth Breaks Ground in UK

Fujifilm Diosynth Biotechnologies (FDB), a cGMP contract development and manufacturing organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies, held a ground breaking ceremony on March 12, 2020 signalling commencement of construction of the company’s new BioCampus at its Billingham, UK location.
 
This BioCampus development will include the construction of 42,000 square foot purpose built office accommodation and visitor centre in addition to making ready the land for potential expansion that could include additional research and development laboratories and new manufacturing facilities.
 
"This will enable us to significantly enhance the quality of the working environment for our existing employees and provide visitors with a fantastic arrival experience," said Paul Found chief operating officer, FDB, UK.
 
The up to £14.5M development is partly supported by the Tees Valley Mayor and Combined Authority (TVCA) through grant funding. It is expected that the new office accommodation will house approximately 250 of FDB’s existing staff and support the addition of further 50 positions at the company’s UK location to support its growing portfolio of partner programs.
 
"Fujifilm Diosynth Biotechnologies is doing fantastic work in our hugely important bioscience sector and creating the skilled jobs we need. Our funding for this new development recognizes its commitment to the region and the opportunities it is providing for local people," said Tees Valley Mayor Ben Houchen."By backing Fujifilm Diosynth Biotechnologies and other organisations such as Teesside University’s centre for excellence and the National Horizons Centre, the Tees Valley is making its mark as a sector leader, driving forward innovation and jobs."
  
The construction is expected to be completed by March 2021.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.